利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

108 条记录 (耗时 0.055 秒)

    Distributed quality-of-service management system
    91.
    发明申请
    Distributed quality-of-service management system 审中-公开
    分布式服务质量管理体系

    公开(公告)号：US20070058669A1

    公开(公告)日：2007-03-15

    申请号：US10566505

    申请日：2004-07-30

    申请人： Matthias Hoffmann ,  Thomas Ketz ,  Vahid Mirbaha

    发明人： Matthias Hoffmann ,  Thomas Ketz ,  Vahid Mirbaha

    IPC分类号： H04J3/16

    CPC分类号： H04W28/10 ,  H04L29/06 ,  H04L47/10 ,  H04L47/11 ,  H04L47/125 ,  H04L47/14 ,  H04L47/19 ,  H04L47/2416 ,  H04L47/30 ,  H04L47/801 ,  H04L47/803 ,  H04L47/823 ,  H04L47/824 ,  H04L69/24 ,  H04L69/32

    摘要： An application unit and a modem unit for mobile communication are provided. The application unit comprises at least one application that exchanges data traffic with at least one protocol stack, wherein said at least one protocol stack transfers data between at least one of the applications and at least one physical interface. The modem unit comprises a broadcast facility for setting up a wireless connection, and at least one transmission protocol stack for transferring data traffic between the at least one physical interface and the broadcast facility. The modem unit collects flow control information about the status of the wireless connection. The flow control information are packed into an IP packet which is sent via the physical interface to the application unit. The application unit uses the received flow control information to optimize the quality of service.

    摘要翻译： 提供了用于移动通信的应用单元和调制解调器单元。 应用单元包括用至少一个协议栈交换数据业务的至少一个应用，其中所述至少一个协议栈在至少一个应用和至少一个物理接口之间传送数据。 调制解调器单元包括用于建立无线连接的广播设施，以及用于在至少一个物理接口和广播设施之间传送数据业务的至少一个传输协议栈。 调制解调器单元收集有关无线连接状态的流量控制信息。 流控制信息被打包到通过物理接口发送到应用单元的IP分组中。 应用单元使用接收到的流量控制信息来优化服务质量。

    Ceramic bodies formed from partially stabilized zirconia
    93.
    发明授权
    Ceramic bodies formed from partially stabilized zirconia 失效
    由部分稳定的氧化锆形成的陶瓷体

    公开(公告)号：US5023217A

    公开(公告)日：1991-06-11

    申请号：US468184

    申请日：1990-01-22

    申请人： Richard Everhart ,  Paul Bosomworth ,  Kenneth Butcher ,  Matthias Hoffmann

    发明人： Richard Everhart ,  Paul Bosomworth ,  Kenneth Butcher ,  Matthias Hoffmann

    IPC分类号： B01D39/20 ,  C04B35/486 ,  C04B35/49 ,  C04B38/06

    CPC分类号： B01D39/2093 ,  C04B35/486 ,  C04B35/49 ,  C04B38/0615

    摘要： The present invention relates to ceramic bodies suitable for use in high temperature applications such as molten metal filters and kiln furniture. The ceramic bodies are formed from partially stabilized zirconia and are characterized by the presence of from about 12% to about 80% by weight zirconia in a monoclinic phase and the balance essentially in a cubic phase at room temperature. The ceramic bodies possess an excellent combination of physical properties including high temperature strength and thermal shock resistance. The invention also relates to the process for forming the ceramic bodies and the thixotropic ceramic slurry used therein.

    摘要翻译： 本发明涉及适用于高温应用的陶瓷体，如熔融金属过滤器和窑具。 陶瓷体由部分稳定的氧化锆形成，其特征在于在单斜晶相中存在约12重量％至约80重量％的氧化锆，余量基本上在室温下为立方相。 陶瓷体具有包括高温强度和耐热冲击性在内的物理性能的优异组合。 本发明还涉及用于形成陶瓷体的方法和其中使用的触变陶瓷浆料。

    AUTOMATIC RECOGNITION OF ANATOMICAL LANDMARKS
    95.
    发明申请
    AUTOMATIC RECOGNITION OF ANATOMICAL LANDMARKS 审中-公开

    公开(公告)号：US20170270663A1

    公开(公告)日：2017-09-21

    申请号：US15459778

    申请日：2017-03-15

    申请人： Matthias Hoffmann ,  Norbert Strobel

    发明人： Matthias Hoffmann ,  Norbert Strobel

    IPC分类号： G06T7/00 ,  A61B5/02 ,  G06T17/20 ,  A61B5/00

    CPC分类号： G06T7/0012 ,  A61B5/02007 ,  A61B5/7271 ,  A61B5/742 ,  G06T7/73 ,  G06T17/20 ,  G06T2207/30101 ,  G06T2207/30172 ,  G06T2210/41

    摘要： A method for automatic recognition of at least one anatomical landmark in a hollow organ of a patient is provided. The method includes providing an image dataset of the hollow organ, establishing or providing a three-dimensional mesh of a surface of the hollow organ from the image dataset, and determining a centerline of the mesh by skeletization. At least one feature is determined for each of a plurality of points on the centerline. A classifier pre-trained on the at least one feature is used for detecting candidates for the at least one anatomical landmark from the plurality of points. The candidates are grouped together with a distance from one another below a threshold. At least one specification determined from the anatomy of the hollow organ is used for confirming or rejecting the candidates for the at least one anatomical landmark. One or more candidates are defined as an anatomical landmark.

    Dipeptidyl peptidase IV inhibitors for the treatment of schizophrenia and depression
    97.
    发明授权
    Dipeptidyl peptidase IV inhibitors for the treatment of schizophrenia and depression 有权
    二肽基肽酶IV抑制剂用于治疗精神分裂症和抑郁症

    公开(公告)号：US08168199B2

    公开(公告)日：2012-05-01

    申请号：US12202774

    申请日：2008-09-02

    申请人： Hans-Ulrich Demuth ,  Ants Kask ,  Huu Phuc Nguyen ,  Stephan von Hoersten ,  Susanne Kruber ,  Matthias Hoffmann

    发明人： Hans-Ulrich Demuth ,  Ants Kask ,  Huu Phuc Nguyen ,  Stephan von Hoersten ,  Susanne Kruber ,  Matthias Hoffmann

    IPC分类号： A61K39/00 ,  A61K39/38

    CPC分类号： A61K31/426 ,  A61K31/40 ,  A61K38/2271 ,  A61K45/06 ,  A61K2300/00

    摘要： A method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of a suitable DP IV inhibitor causes the reduction of activity in the enzyme dipeptidyl peptidase (DP IV or CD 26) or of DP IV-like enzyme activity in the brain of mammals and leads as a causal consequence to a reduced degradation of the neuropeptide Y (NPY) and similar substrates by DP IV and DP IV-like enzymes. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1-36). As a consequence of the resulting enhanced stability of the endogenous NPY (1-36) caused by the inhibition of DP IV activity, NPY activity is prolonged thereby resulting among other things in functionally active NPY Y1 receptor activity thereby facilitating antidepressive, anxiolytic, analgesic, antihypertension and other neurological effects.

    摘要翻译： 用于治疗性处理动物，包括人的用于心身，抑郁和神经精神疾病如焦虑，抑郁，失眠，精神分裂症，癫痫，痉挛和慢性疼痛的方法。 施用合适的DP IV抑制剂导致哺乳动物脑中的酶二肽基肽酶（DP IV或CD 26）或DP IV样酶活性的活性降低，并导致神经肽降低的降低的因果结果 Y（NPY）和类似底物的DP IV和DP IV样酶。 这种治疗将导致功能活跃的神经元NPY（1-36）的浓度降低或延迟。 由于由抑制DP IV活性引起的内源性NPY（1-36）的增强的稳定性，NPY活性延长，从而导致功能活性的NPY Y1受体活性，从而促进抗抑郁，抗焦虑，止痛， 抗高血压等神经功能。

    DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA AND DEPRESSION
    99.
    发明申请
    DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA AND DEPRESSION 有权
    用于治疗精神分裂症和抑郁症的替代肽第四剂抑制剂

    公开(公告)号：US20090062203A1

    公开(公告)日：2009-03-05

    申请号：US12202774

    申请日：2008-09-02

    申请人： Hans-Ulrich Demuth ,  Ants Kask ,  Huu Phuc Nguyen ,  Stephan von Hoersten ,  Susanne Kruber ,  Matthias Hoffmann

    发明人： Hans-Ulrich Demuth ,  Ants Kask ,  Huu Phuc Nguyen ,  Stephan von Hoersten ,  Susanne Kruber ,  Matthias Hoffmann

    IPC分类号： A61K38/17 ,  A61K38/05

    CPC分类号： A61K31/426 ,  A61K31/40 ,  A61K38/2271 ,  A61K45/06 ,  A61K2300/00

    摘要： A method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of a suitable DP IV inhibitor causes the reduction of activity in the enzyme dipeptidyl peptidase (DP IV or CD 26) or of DP IV-like enzyme activity in the brain of mammals and leads as a causal consequence to a reduced degradation of the neuropeptide Y (NPY) and similar substrates by DP IV and DP IV-like enzymes. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1-36). As a consequence of the resulting enhanced stability of the endogenous NPY (1-36) caused by the inhibition of DP IV activity, NPY activity is prolonged thereby resulting among other things in functionally active NPY Y1 receptor activity thereby facilitating antidepressive, anxiolytic, analgesic, antihypertension and other neurological effects.

    摘要翻译： 用于治疗性处理动物，包括人的用于心身，抑郁和神经精神疾病如焦虑，抑郁，失眠，精神分裂症，癫痫，痉挛和慢性疼痛的方法。 施用合适的DP IV抑制剂导致哺乳动物脑中的酶二肽基肽酶（DP IV或CD 26）或DP IV样酶活性的活性降低，并导致神经肽降低的降低的因果结果 Y（NPY）和类似底物的DP IV和DP IV样酶。 这种治疗将导致功能活跃的神经元NPY（1-36）的浓度降低或延迟。 由于由抑制DP IV活性引起的内源性NPY（1-36）的增强的稳定性，NPY活性延长，从而导致功能活性的NPY Y1受体活性，从而促进抗抑郁，抗焦虑，止痛， 抗高血压等神经功能。

    Dipeptidyl peptidase IV inhibitors for the treatment of anxiety
    100.
    发明授权
    Dipeptidyl peptidase IV inhibitors for the treatment of anxiety 有权
    二肽基肽酶IV抑制剂治疗焦虑症

    公开(公告)号：US07435420B2

    公开(公告)日：2008-10-14

    申请号：US11397281

    申请日：2006-04-04

    申请人： Stephan von Hoersten ,  Ants Kask ,  Hans-Ulrich Demuth ,  Huu Phuc Nguyen ,  Susanne Kruber ,  Matthias Hoffmann

    发明人： Stephan von Hoersten ,  Ants Kask ,  Hans-Ulrich Demuth ,  Huu Phuc Nguyen ,  Susanne Kruber ,  Matthias Hoffmann

    IPC分类号： A61K39/00 ,  A61K39/38 ,  A61K35/00 ,  A01N37/18

    CPC分类号： A61K31/426 ,  A61K31/40 ,  A61K38/2271 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention discloses a method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain.Administration of a suitable DP IV inhibitor causes the reduction of activity in the enzyme dipeptidyl peptidase (DP IV or CD 26) or of DP IV—like enzyme activity in the brain of mammals and leads as a causal consequence to a reduced degradation of the neuropeptide Y (NPY) and similar substrates by DP IV and DP IV-like enzymes. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1-36). As a consequence of the resulting enhanced stability of the endogenous NPY (1-36) caused by the inhibition of DP IV activity, NPY activity is prolonged thereby resulting among other things in functionally active NPY Y1 receptor activity thereby facilitating antidepressive, anxiolytic, analgesic, antihypertension and other neurological effects.

    摘要翻译： 本发明公开了一种治疗性处理动物（包括人）用于心身，抑郁和神经精神疾病如焦虑，抑郁，失眠，精神分裂症，癫痫，痉挛和慢性疼痛的方法。 施用合适的DP IV抑制剂导致哺乳动物脑中的酶二肽基肽酶（DP IV或CD 26）或DP IV样酶活性的活性降低，并导致神经肽降低的降低的因果结果 Y（NPY）和类似底物的DP IV和DP IV样酶。 这种治疗将导致功能活跃的神经元NPY（1-36）的浓度降低或延迟。 由于由抑制DP IV活性引起的内源性NPY（1-36）的增强的稳定性，NPY活性延长，从而导致功能活性的NPY Y1受体活性，从而促进抗抑郁，抗焦虑，止痛， 抗高血压等神经功能。